MARKET

ACRX

ACRX

Acelrx Pharma
NASDAQ
2.350
+0.070
+3.07%
Closed 16:49 11/25 EST
OPEN
2.280
PREV CLOSE
2.280
HIGH
2.390
LOW
2.210
VOLUME
34.98K
TURNOVER
--
52 WEEK HIGH
13.70
52 WEEK LOW
1.760
MARKET CAP
17.51M
P/E (TTM)
0.3783
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 11/21 21:32
Sector Update: Health Care Stocks Fading in Late Tuesday Trading
Sector Update: Health Care Stocks Fading in Late Tuesday Trading
MT Newswires · 11/15 15:57
Sector Update: Health Care Stocks Posting Small Advance
Sector Update: Health Care Stocks Posting Small Advance
MT Newswires · 11/15 13:01
BRIEF-AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results, Provides Corporate Update
Reuters · 11/14 21:45
AcelRx Pharmaceuticals GAAP EPS of -$0.94 beats by $0.26, revenue of $0.51M misses by $0.12M
Seekingalpha · 11/14 21:02
-- Earnings Flash (ACRX) ACELRX PHARMACEUTICALS Reports Q3 Revenue $507,000, vs. Street Est of $0.625M
-- Earnings Flash (ACRX) ACELRX PHARMACEUTICALS Reports Q3 Revenue $507,000, vs. Street Est of $0.625M
MT Newswires · 11/14 16:11
Notable earnings after Monday's close
Seekingalpha · 11/13 22:35
AcelRx Pharmaceuticals Q3 2022 Earnings Preview
Seekingalpha · 11/11 22:35
More
About ACRX
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Its sufentanil sublingual products include DSUVIA, DZUVEO and Zalviso, which are focused on the treatment of moderate-to-severe acute pain in a medically supervised setting. Its pre-filled syringe product candidates include Ephedrine and Phenylephrine. Its nafamostat mesylate product candidates include Niyad, which is a regional anticoagulant for injection into the extracorporeal circuit, and LTX-608, which is a nafamostat formulation for antiviral treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), and acute pancreatitis.

Webull offers kinds of AcelRx Pharmaceuticals Inc stock information, including NASDAQ:ACRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACRX stock methods without spending real money on the virtual paper trading platform.